AUTL - オ―トルス・セラピュ―ティクス （Autolus Therapeutics plc） オ―トルス・セラピュ―ティクスAUTLのチャート
AUTLの企業情報
| symbol | AUTL |
|---|---|
| 会社名 | Autolus Therapeutics PLC （オ―トルス・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Autolus Therapeutics plc formerly Autolus Therapeutics Limited is a development-stage biopharmaceutical company. The company is engaged in developing programmed T-cell therapies for the treatment of cancer. The Company''s clinical-stage product candidates target hematological cancers. Its products candidates include AUTO2 AUTO3 AUTO4 and AUTO6. AUTO2 is a dual-targeting programmed T-cell therapy for the treatment of relapsed or refractory multiple myeloma targeting B-cell Maturation Antigen and the transmembrane activator. AUTO3 is a T-cell therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma and pediatric relapsed acute B lymphocytic leukemia. Its AUTO4 is a T-cell therapy for the treatment of peripheral T-cell lymphoma. オ―トルス・セラピュ―ティクスはイギリスのバイオ医薬品企業。主にがん治療に対する次世代のT細胞療法の開発に従事する。同社は独自のモジュ―ル型T細胞プログラミング技術を使用して、より正確にがん細胞を認識し、防御機能を破壊して、がん細胞を排除するより活性的なT細胞療法を開発する。本社所在地はロンドン。 Autolus Therapeutics plcis a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. |
| 本社所在地 | Forest House 58 Wood Lane London W12 7RZ GBR |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +44 20-3829-6230 |
| 設立年月日 | 43132 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | 126人 |
| url | www.autolus.com |
| nasdaq_url | https://www.nasdaq.com/symbol/autl |
| adr_tso | 10147059 |
| EBITDA | EBITDA（百万ドル） ー |
| 終値（lastsale） | 28.01 |
| 時価総額（marketcap） | 284219122.59 |
| 時価総額 | 時価総額（百万ドル） 151.882 |
| 売上高 | 売上高（百万ドル） -- |
| 企業価値(EV) | 企業価値(EV)（百万ドル） ー |
| 当期純利益 | 当期純利益（百万ドル） -- |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 30 September 2017 Autolus Therapeutics Ltd - ADR revenues increased 40% to $1.7M. Net loss increased 57% to $19.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 56% to $14.9M (expense) General and administrative - Balancing v increase of 86% to $7.1M (expense). |
AUTLのテクニカル分析
AUTLのニュース
Wells Fargo Assumes Autolus Therapeutics plc at Overweight 2023/03/27 11:56:06 Investing.com
https://www.investing.com/news/pro/wells-fargo-assumes-autolus-therapeutics-plc-at-overweight-432SI-3040888
Autolus Therapeutics finance chief steps down (NASDAQ:AUTL) 2023/03/14 11:20:23 Seeking Alpha
A clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, Autolus Therapeutics (AUTL) said that Dr. Lucinda Crabtree has provided notice of…
Autolus Therapeutics announces resignation of Chief Financial Officer 2023/03/14 11:00:00 GlobeNewswire
- Dr. Lucinda Crabtree to step down with effect from Q3 2023 –
Autolus Therapeutics plc PT Raised to $2.70 at Goldman Sachs 2023/03/10 11:01:02 Investing.com
https://www.investing.com/news/pro/autolus-therapeutics-plc-pt-raised-to-270-at-goldman-sachs-432SI-3027359
Autolus Therapeutics GAAP EPS of -$1.57 beats by $0.06, revenue of $6.36M misses by $4.47M (NASDAQ:AUTL) 2023/03/07 12:06:30 Seeking Alpha
Autolus Therapeutics press release (NASDAQ:AUTL): FY GAAP EPS of -$1.57 beats by $0.06.Revenue of $6.36M (+173.0% Y/Y) misses by $4.47M.
Autolus'' Blood Cancer CAR T-Cell Therapy Receives Promising Innovative Medicine In UK 2021/08/09 15:57:11 Benzinga
The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted Promising Innovative Medicine (PIM) designation to Autolus Therapeutics plc''s (NASDAQ: AUTL ) AUTO1 (obecabtagene Full story available on Benzinga.com
Autolus Therapeutics plc 2021 Q2 - Results - Earnings Call Presentation 2021/08/06 16:10:34 Seeking Alpha
Autolus Stock Jumps On Cancer mRNA Therapeutics Agreement With Moderna 2021/08/02 12:48:57 Benzinga
Autolus Therapeutics plc (NASDAQ: AUTL ) has granted Moderna Inc (NASDAQ: MRNA ) an exclusive license to develop and commercialize mRNA therapeutics incorporating Autolus'' proprietary Full story available on Benzinga.com
Autolus Announces Appointment of Edgar Braendle, M.D., Ph.D., as Chief Development Officer 2021/07/15 11:00:00 Intrado Digital Media
LONDON, July 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Edgar Braendle M.D., Ph.D., as chief development officer. Dr Braendle is joining Autolus executive team today and will lead the company''s development organization.
Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William Blair Biotech Focus Conference 2021 on July 14, 2021 2021/07/08 11:00:00 Intrado Digital Media
LONDON, July 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2021 financial results and operational highlights before open of U.S. markets on Thursday, August 5, 2021.
Autolus Announces Appointment of Edgar Braendle, M.D., Ph.D., as Chief Development Officer 2021/07/15 11:00:00 Intrado Digital Media
LONDON, July 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Edgar Braendle M.D., Ph.D., as chief development officer. Dr Braendle is joining Autolus executive team today and will lead the company''s development organization.
Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William Blair Biotech Focus Conference 2021 on July 14, 2021 2021/07/08 11:00:00 Intrado Digital Media
LONDON, July 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2021 financial results and operational highlights before open of U.S. markets on Thursday, August 5, 2021.
Autolus Therapeutics'' obe-cel shows high clinical activity in blood cancers, shares rise 5% 2021/06/11 11:39:37 Seeking Alpha
Autolus Therapeutics Announces an Additional Nature Publication for AUTO1- Data suggest that long term durability of response in acute lymphoblastic leukemia patients treated with AUTO1 is due to an enrichment of Stem Cell Memory T cells - 2021/05/25 00:00:00 BioSpace
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced a publication in Nature Cancer that gives new insight into the mechanism of long-term durability of effect in acute lymphoblastic leukemia patients treated with AUTO1.
Autolus Notice of Annual General Meeting (AGM) on Friday, June 18, 2021 2021/05/21 00:00:00 BioSpace
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, posted notice of its Annual General Meeting to shareholders, which can be viewed and downloaded from www.autolus.com.